# US 2026/0235630 A1 · Method for immunologically measuring hemoglobin using deglycosylated haptoglobin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0235630 A1
- Document ID: US20260235630A1
- Status: Published application
- Kind: A1
- Application number: 19/160,448
- Filed: 2024-02-27
- Published: 2026-08-13
- Earliest claimed: 2023-02-27
- Assignees: Eiken Kagaku Kabushiki Kaisha
- Applicants: Eiken Kagaku Kabushiki Kaisha
- Inventors: Mitsuru MAKINODAN; Kouhei KAWAGUCHI; Megumi YUI; Koichi FUJII; Naoyuki KOZUKA
- Web page: https://patentgrep.com/patent/US20260235630A1

## CPC

- G01N 33/721: {Haemoglobin}
- C07K 14/435: from animals; from humans
- C07K 14/805: Haemoglobins; Myoglobins
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C12Y 302/01096: Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
- C12Y 305/01052: Peptide-N4-(N-acetyl-beta-glucosaminyl)asparagine amidase (3.5.1.52), i.e. glycopeptidase
- G01N 33/543: with an insoluble carrier for immobilising immunochemicals
- C12Y 302/01098: Glucan 1,4-alpha-maltohexaosidase (3.2.1.98)
- G01N 2333/805: Haemoglobins; Myoglobins
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Y: ENZYMES

## Abstract

An immunological measurement method for hemoglobin, comprising a step of performing the immunological measurement using an anti-hemoglobin antibody under coexistence of the hemoglobin and haptoglobin, the haptoglobin having a characteristic (1) below: (1) at least a portion of an N-linked glycan is deleted. The present invention further provides a method for suppressing change in measurement values of hemoglobin, a method and a solution for stabilizing hemoglobin, a hemoglobin measurement kit, and the haptoglobin and a method for producing the same. According to the present invention, hemoglobin can be measured while suppressing haptoglobin-associated change in hemoglobin measurement values.

## Claims

### Claim at position 1

1-39. (canceled)

### Claim 40

An immunological measurement method for hemoglobin, comprising
a step of performing the immunological measurement using an anti-hemoglobin antibody under coexistence of the hemoglobin and haptoglobin,
the haptoglobin having a characteristic (1) below:
(1) at least a portion of an N-linked glycan is deleted;
or
a method for suppressing, in immunological measurement of hemoglobin, change in measurement values of the hemoglobin, comprising
a step of performing the immunological measurement using an anti-hemoglobin antibody under coexistence of the hemoglobin and haptoglobin,
the method using as the haptoglobin a haptoglobin having a characteristic (1) below:
(1) at least a portion of an N-linked glycan is deleted;
or
a method for stabilizing hemoglobin, comprising a step of allowing hemoglobin to coexist with haptoglobin having a characteristic (1) below:
(1) at least a portion of an N-linked glycan is deleted;
or
haptoglobin having an N-linked glycan, the glycan of the N-linked glycan being one N-acetylglucosamine residue or only a glycan in which one fucose residue is bound to one N-acetylglucosamine residue;
or
a method for producing haptoglobin, comprising a step of subjecting naturally-derived haptoglobin to a glycosidase treatment, and satisfying (a) and (b) below:
(a) the naturally-derived haptoglobin is not subjected to a heat shock of 90° C. or higher prior to the glycosidase treatment; and
(b) SDS is not allowed to coexist during the glycosidase treatment.

### Claim 41 (depends on 40)

The immunological measurement method according to claim 40, wherein the haptoglobin further has a characteristic (2) below:
(2) when 3.1 μmol of hemoglobin is stored at 37° C. for 7 days in 500 μL of a buffer solution containing 3.1 μmol of the haptoglobin, a residual ratio of the hemoglobin is 70% or more.

### Claim 42 (depends on 40)

The immunological measurement method according to claim 40, wherein the characteristic (1) is a characteristic (1a) below:
(1a) a difference between a molecular weight of a β-chain in the haptoglobin treated with peptide-N-glycosidase (PNGase) and a molecular weight of a β-chain in an untreated haptoglobin is 6,500 or less.

### Claim 43 (depends on 40)

The immunological measurement method according to claim 40, wherein the haptoglobin has no N-linked glycan.

### Claim 44 (depends on 40)

The immunological measurement method according to claim 40, wherein the N-linked glycan present in the haptoglobin from which at least a portion of the N-linked glycan is deleted is one N-acetylglucosamine residue or a glycan in which one fucose residue is bound to one N-acetylglucosamine residue.

### Claim 45 (depends on 40)

The immunological measurement method according to claim 40, wherein the hemoglobin is contained in feces, blood, serum, plasma, urine, sputum, or saliva.

### Claim 46 (depends on 40)

The immunological measurement method according to claim 40, wherein at least one type of the anti-hemoglobin antibody is supported on an insoluble carrier;
wherein optionally the insoluble carrier is an insoluble particle.

### Claim 47 (depends on 40)

The immunological measurement method according to claim 40, wherein the immunological measurement method is an immune agglutination method.

### Claim 48 (depends on 40)

The method for stabilizing hemoglobin according to claim 40, wherein the haptoglobin further has a characteristic (2) below:
(2) when 3.1 μmol of hemoglobin is stored at 37° C. for 7 days in 500 μL of a buffer solution containing 3.1 μmol of the haptoglobin, a residual ratio of the hemoglobin is 70% or more.

### Claim 49

A solution for stabilizing hemoglobin, comprising haptoglobin having a characteristic (1) below:
(1) at least a portion of an N-linked glycan is deleted;
or
haptoglobin having characteristics (1) and (2) below:
(1) at least a portion of an N-linked glycan is deleted; and
(2) when 3.1 μmol of hemoglobin is stored at 37° C. for 7 days in 500 μL of a buffer solution containing 3.1 μmol of the haptoglobin, a residual ratio of the hemoglobin is 70% or more.

### Claim 50 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the haptoglobin further has a characteristic (2) below:
(2) when 3.1 μmol of hemoglobin is stored at 37° C. for 7 days in 500 μL of a buffer solution containing 3.1 μmol of the haptoglobin, a residual ratio of the hemoglobin is 70% or more.

### Claim 51 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the characteristic (1) is a characteristic (1a) below:
(1a) a difference between a molecular weight of a β-chain in the haptoglobin treated with peptide-N-glycosidase (PNGase) and a molecular weight of a β-chain in an untreated haptoglobin is 6,500 or less.

### Claim 52 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the haptoglobin has no N-linked glycan.

### Claim 53 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the haptoglobin is haptoglobin that is naturally-derived and treated with peptide-N-glycosidase (PNGase).

### Claim 54 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the N-linked glycan present in the haptoglobin from which at least a portion of the N-linked glycan is deleted is one N-acetylglucosamine residue or a glycan in which one fucose residue is bound to one N-acetylglucosamine residue.

### Claim 55 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the haptoglobin is haptoglobin that is naturally-derived and treated with endo-β-N-acetylglucosaminidase (ENGase).

### Claim 56 (depends on 49)

The solution for stabilizing hemoglobin according to claim 49, wherein the hemoglobin is contained in feces, blood, serum, plasma, urine, sputum, or saliva.

### Claim 57 (depends on 49)

A hemoglobin measurement kit for immunologically measuring hemoglobin, comprising:
the solution for stabilizing hemoglobin according to claim 49; and
a reagent containing an anti-hemoglobin antibody.

### Claim 58 (depends on 57)

The hemoglobin measurement kit according to claim 57, wherein at least one type of the anti-hemoglobin antibody is supported on an insoluble carrier;
herein optionally the insoluble carrier is an insoluble particle.

### Claim 59 (depends on 21)

The hemoglobin measurement kit according to claim 21, wherein the reagent is a reagent for an immune agglutination method.
